Syqe Medical Cannabis Inhaler Draws Big Pharma Interest from Teva

syqe inhaler

Israeli cannabis device maker Syqe Medical, which includes Philip Morris International as a major investor, has signed Teva Pharmaceuticals (NYSE: TEVA) to distribute its inhaler following its approval by the Health Ministry next year. In addition to the distribution agreement, the companies will jointly set up support and training for patients and medical professionals using a dedicated team of nurses.

The pocket-sized Syqe Inhaler uses selective 100 microgram dosing precision that allows patients to control accurately the delivery, attempting to overcome one of the major barriers to adoption of medical cannabis by doctors, the lack of standardization. The company has tested a similar device in hospitals in a clinical trial that demonstrated its dosing precision superiority to other modes of THC administration.

Read Shoshanna Solomon’s “In global first, Teva signs deal to market medical marijuana inhaler”:

Published by NCV Newswire
NCV Newswire
The NCV Newswire by New Cannabis Ventures aims to curate high quality content and information about leading cannabis companies to help our readers filter out the noise and to stay on top of the most important cannabis business news. The NCV Newswire is hand-curated by an editor and not automated in anyway. Have a confidential news tip? Get in touch.

Get Our Sunday Newsletter